Sunday, February 3, 2019

(LML) Infolep monthly update with a selection of leprosy publications - February 2019

Leprosy Mailing List – February 3,  2019
Ref.:    (LML) Infolep monthly update with a selection of leprosy publications - February 2019
From:  Jiske Erlings, Amsterdam, the Netherlands


Dear colleagues,
Infolep provides scientists, professionals and others working in the field of leprosy with up to date knowledge and information to support their daily work.
Every month we send you an overview of (scientific) publications on leprosy and related subjects recently added to Infolep website.

To search the full collection, please visit www.leprosy-information.org.
Feel free to contact me to receive the full text versions if a link to the full text is not included or for assistance with your literature research. You are also invited to send us your publications on leprosy for inclusion in the portal.

With warm regards,

Jiske Erlings, j.erlings@leprastichting.nl
Infolep Information officer
 
Highlighted publication
Zero Discrimination: Ending the Stigma of Leprosy
ILEP. 2019.
Download PDF

Global Appeal 2019 to End Stigma and Discrimination Against People Affected by Leprosy.
Download PDF

Picturing health: a new face for leprosy.
Kumar A, Lambert S, Lockwood DNJ. Lancet. 2019 Jan 25.
Download PDF

Infolep WorldLeprosyDay2019 overview of publications on leprosy related stigma, discrimination and mental health:
https://www.leprosy-information.org/keytopic/world-leprosy-day-2019

WASH and health working together A 'how-to' guide for Neglected Tropical Disease programmes.
World Health Organization, Neglected Tropical Disease NGO Network (NNN). 2019
PDF and interactive toolkit
New publications
Abandoning the stigma of leprosy.
Lancet. 2019. Feb 2.
Download PDF
 


Clinicopathological correlation of leprosy and response to treatment in Eastern Saudi Arabia.
Alakloby OM, Alabdulkareem AS, M. Aljabre SH, et al. J Dermatol Dermatol Surg. 2019; 22(1):30-34.
Download PDF
 


Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.
Amorim FM, Nobre ML, Nascimento LS, et al. PLoS Negl Trop Dis. 2019; 13(1):e0007089.
Download PDF
 


A five year study of profile of leprosy patients attending a tertiary care hospital in Manipur.
Bachaspatimayum R, Hafi BN, Thokchom NS, et al. Indian J Lepr. 2018; 90:189-195.
Download PDF
 


Mycobacterium leprae Recombinant Antigen Induces High Expression of Multifunction T Lymphocytes and Is Promising as a Specific Vaccine for Leprosy.
Bezerra-Santos M, do Vale-Simon M, Barreto AS, et al. Front Immunol. 2018 Dec 12;9:2920.
Download PDF
 


Catalina Devandas Aguilar: empowering people with disabilities.
Bull World Health Organ. 2019 Jan 1;97(1):8-9.
Download PDF
 


'Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-2015' - Author's reply.
Cambau E, Saunderson P, Gillini. Clin Microbiol Infect. 2019 Jan 22.
Read abstract
 


Cataract surgery in leprosy: Quest for perfection.
Chowdhury S, Sneha, Priti, et al. Acta scientific medical sciences. 2019; 3(2):120-123.
Download PDF
 


Fingerstick test quantifying humoral and cellular biomarkers indicative for M. leprae infection.
Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, et al. Clin Biochem. 2019 Jan 26.
Read abstract
 


T'sarat/leprosy: paths taken by relatives of former patients treated in the asylum environment.
Costa Pinheiro MG, Albino Simpson C, Nunes de Miranda FA, et al. 2019; 11(1):47-52.
Download PDF
 


Assessing the impact of the twin track socio-economic intervention on reducing leprosy-related stigma in Cirebon district, Indonesia.
Dadun D, Peters RMH, Van Brakel WH, et al. Int J Environ Res Public Health. 2019; 16(3).
Download PDF
 


Inclusive medical rehabilitation for persons with disability due to leprosy, lymphatic filariasis, and diabetes mellitus: Mapping the gap in three leprosy endemic districts in Indonesia.
Denny HM, Darmawan Y, Ginandjar P, et al. bioRxivorg. 2019:1-14.
Download PDF
 


Disability due to leprosy: a socio-demographic study in Leprosy Hospital, Chamba, Himachal Pradesh.
Dixit P, Dhiman AK. Int J Community Med Public Health. 2019; 6(2):590-593.
Download PDF
 


Notch signaling induces lymphoproliferation, T helper cell activation and Th1/Th2 differentiation in leprosy.
Dua B, Upadhyay R, Natarajan M, et al. Immunol. Lett. 2019.
Read abstract
 


Analysis of the rs2476601 polymorphism of PTPN22 in Mexican mestizo patients with leprosy.
Escamilla-Tilch M, Pérez-Suárez TG, Torres-Carrillo NM, et al.  Biomed Rep. 2019 Feb;10(2):127-132.
Download PDF
 


Accuracy of enzyme-linked immunosorbent assays (ELISAs) in detecting antibodies against in leprosy patients: A systematic review and meta-analysis.
Espinosa OA, Benevides Ferreira SM, Longhi Palacio FG, et al. Can J Infect Dis Med Microbiol. 2018; 2018:11.
Download PDF
 


Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Fava VM, Xu YZ, Lettre G, et al. bioRxivorg. 2019.
Download PDF
 


Evaluation of the physical limitations, psychosocial aspects and quality of life of people affected by leprosy.
Ferreira Silva PM, Esteves Pereira L, Lima Ribeiro L, et al. Revista de pesquisa, cuidado é fundamental online. 2019; 11(1):211-215.
Download PDF
 


Leprosy and rhinoscleroma: A rare case of concurrence: A case study.
Ghazizadeh M, Yazdani N. Arch Clin Infect Dis. 2019:e63233.
Download PDF
 


Lucio phenomenon mimicking antiphospholipid syndrome: the occurrence of antiphospholipid antibodies in a leprosy patient.
Guevara BEK, Saleem S, Chen WT, et al. J Cutan Pathol. 2019 Jan 21.
Read abstract
 


Endoplasmic reticulum stress markers and their possible implications in leprosy's pathogenesis.
Hirai KE, de Sousa JR, Silva LM, et al. Dis. Markers. 2018.
Download PDF
 


Unusual association of leprosy with Lucio phenomenon with secondary antiphospholipid antibody syndrome and ischemic stroke.
Kumar S, Kalita J, Rao RN, Misra UK. Neurol India. 2019 Jan-Feb;67(Supplement):S150-S151.
Read abstract
 


Leprosy: A great ımıtator.
Kundakçi N, Cengizhan E. Clin. Dermatol. 2019.
Read abstract
 


A study on trends and patterns of leprosy in Guyana during a ten year period, 2007-2016.
Kurup R, Haynes U, Mentore G. Indian J Lepr. 2018; 90:207-216.
Download PDF
 


Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.
Leturiondo AL, Noronha AB, do Nascimento MOO, et al. 2019; 19(1):22.
Download PDF
 


Chronic aspects of leprosy—neglected but important.
Lockwood DNJ. Trans. R. Soc. Trop. Med. Hyg. 2019.
Read abstract
 


Insights on Mycobacterium leprae efflux pumps and their implications in drug resistance and virulence.
Machado D, Lecorche E, Mougari F, et al. Front Microbiol. 2018 Dec 13;9:3072.
Read abstract
 


Photo distributed leprosy- An atypical case of borderline lepromatous leprosy.
Nagar R, Patil S. Indian J Lepr. 2018; 90:241-244.
Download PDF
 


A review of the ophthalmic manifestations of leprosy.
Ogborogu EU, Omoti AE, Edema OT, et al. Annals of medical and surgical practice. 2018; 3(2):60-70.
Download PDF
 


[Clinical and epidemiological profile of patients with hanseniasis in a reference unit in the state of Pará].
do Quaresma MSM, da Souza LSC, da Silva FBM, et al. Acervo Saúde. 2018; (18):e269.
Download PDF
 


A 5 year study of leprosy patients in a tertiary care centre.
Rashmi M, Kishan N, Varun J, et al. Indian journal of clinical and experimental dermatology. 2018; 4(3):232-236.
Read abstract
 


Neglected tropical diseases in children: An assessment of gaps in research prioritization.
Rees CA, Hotez PJ, Monuteaux MC, Niescierenko M, Bourgeois FT. PLoS Negl Trop Dis. 2019 Jan 29;13(1):e0007111.
Download PDF
 


Clinical profile of leprosy cases registered in a hospital in Paraguay, 2013 to 2015.
Rios-González CM. Indian J Lepr. 2018; 90:249-251.
Download PDF
 


[Hansen's disease: a rare presentation with the involvement of 20 nails – case report].
Rodrigues MM, Cordeiro RN, da Santos MÁR, et al. Braz. J. Hea. 2019; 2(2):718-726.
Download PDF
 


British red squirrels remain the only known wild rodent host for leprosy bacilli.
Schilling A-K, Avanzi C, Ulrich RG, et al. Front Vet Sci. 2019.
Read abstract
 


Mycobacterium lepromatosis lepromatous leprosy in US citizen who traveled to disease-endemic areas.
Sharma G, Sharma VD. Emerg Infect Dis. 2019 Feb;25(2):389-390.
Download PDF
 


Heteroexpression of Mycobacterium leprae hypothetical protein ML0190 provides protection against DNA-alkylating agent methyl methanesulfonate.
Sharma M, Akula D, Mohan M, et al. Biochem. Biophys. Res. Commun. 2019.
Read abstract
 


Evaluation of the physical limitations, psychosocial aspects and quality of life of people affected by leprosy.
Silva PMF, Pereira LE, Ribeiro LL, et al. Revista de pesquisa, cuidado é fundamental online. 2019; 11(1):211-215.
Download PDF
 


Involvement of TNF-producing CD8 effector memory T cells with immunopathogenesis of erythema nodosum leprosum in leprosy patients.
Silva PHL, Santos LN, Mendes MA, et al. Am. J. Trop. Med. Hyg. 2019.
Read abstract
 


Community knowledge, attitude, and perceived stigma of leprosy amongst community members living in Dhanusha and Parsa districts of Southern Central Nepal.
Singh R, Singh B, Mahato S. PLoS Negl Trop Dis. 2019 Jan 11;13(1):e0007075.
Download PDF
 


Poor treatment compliance leads to a higher mutation for rifampicin resistance in multibacillary leprosy patients.
Siskawati Y, Effendi EH, Legiawati L, et al. Med J Indones. 2018; 27(4):237-243.
Download PDF
 


Validation of an instrument for the evaluation of adolescents' knowledge about Hansen's disease.
Soares JEF, da Soares NLS, de Freitas BHBM, et al. Acta Paul Enferm. 2018; 31(5):480-488.
Download PDF
 


Leprosy survey among rural communities and wild armadillos from Amazonas state, Northern Brazil.
Stefani MMA, Rosa PS, Costa MB, et al. PLoS ONE. 2019; 14(1):e0209491.
Download PDF
 


Leprosy- control through Superfoods.
Thapar P. Acta scientific microbiology. 2019; 3(2):43-45.
Download PDF
 


Survival of Mycobacterium leprae and association with Acanthamoeba from environmental samples in the inhabitant areas of active leprosy cases: A cross sectional study from endemic pockets of Purulia, West Bengal.
Turankar RP, Lavania M, Darlong J, et al. Infect. Genet. Evol. 2019.
Read abstract
 


Transcription factors STAT-4, STAT-6 and CREB regulate Th1/Th2 response in leprosy patients: effect of M. leprae antigens.
Upadhyay R, Dua B, Sharma B, et al. BMC Infect. Dis. 2019; 19(1):52.
Download PDF
 


Life after leprosy treatment discharge: Physical and social limitations.
Vieira CSCA, Lobato ML, Figueira MCS, et al. Indian J Lepr. 2018; 90:177-188.
Download PDF
 


Journals & Newsletters
Disability, CBR & Inclusive Development: http://dcidj.org/

Hansenologia Internationalis: http://www.ilsl.br/revista/atual.php

Indian Journal of Leprosy: http://www.ijl.org.in/index.html

Leprosy Review: https://www.lepra.org.uk/Pages/FAQs/Category/volume-89
Leprosy Review Repository (1928-2001) : http://leprev.ilsl.br/arquivo.php

Plos Neglected Tropical Diseases: http://journals.plos.org/plosntds/

Revista de Leprología:
http://www.leprosy-information.org/resource/revista-de-leprologia

WHO Goodwill Ambassador's Newsletter for the elimination of leprosy:
http://www.smhf.or.jp/e/ambassador/index.html

 
Websites & Services


LML - S Deepak, B Naafs, S Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) World Leprosy Day 2019 Celebration in Ghana

Leprosy Mailing List – February 1,  2019
Ref.:  (LML)   World Leprosy Day 2019 Celebration in Ghana
From:  Benedict Quao,  Cape-Coast, Ghana


Dear Pieter,


Good morning.

I will be grateful if the following piece is considered for posting on the leprosy mailing list"

To mark the World Leprosy Day celebration in Ghana, a service was organized at the Ankaful Leprosy General Hospital in Cape Coast, which serves as the National Referral Hospital for complications in leprosy, and greatly supported by the resident ILEP representative in Ghana, Father George Abram.

In attendance were the representative of the Regional Director of Health Services (Central Region), other stakeholder representatives, representatives of persons affected by leprosy, currently admitted patients and persons living with disabilities due to leprosy living in surrounding community and from the St Clare's Home at Ahotokrom.

The media (TV, Radio and print) were also on hand to cover the event, which was aimed at creating awareness on the disease and the plight of many persons living with disabilities due to leprosy facing discrimination, stigma and prejudice in the country. We also greatly utilized social media (through various WhatsApp platforms) to advertise the World Leprosy Day 2019 in the preceding week. In various regions too, disease control officers engaged local radio stations in discussions to educate the populace on the early signs of the disease and encourage an end to discrimination, stigma and prejudice. 

There has been a tremendous response especially following the carriage of the message by the National Daily, the Daily Graphic (online version: https://www.graphic.com.gh/news/general-news/ghananews-leprosy-not-curse-stop-spurning-sufferers-public-urged.html). At the just ended Annual review meeting one of the wonderful stories shared was that of the report on the sides of the conference that an individual on the register who had defaulted (and failed retrieval despite many attempts), on hearing the radio message surrounding the WMD 2019, had presented to a health facility and was ready to resume treatment.

We want to share these experiences to encourage all involved in leprosy elimination activities on the need to continue to use the World Leprosy Day as a strong advocacy tool for the maintenance of awareness of the disease even when the case load has declined dramatically. Also, to point out the powerful partner we have in the media as a tool for advocacy and public awareness. We share with all a banner we created for the day that we utilized on various social media platforms.

Thank you.

Regards,

Benedict


LML - S Deepak, B Naafs, S Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) 20th International Leprosy Congress abstract submission

Leprosy Mailing List – January 31,  2019
Ref.:  (LML) 20th International Leprosy Congress abstract submission 
From:  Marivic Balagon, Cebu, the Philippines


Dear Colleague,

Greetings from the Philippines!

On behalf of the Scientific Organizing Committee for the 20th International Leprosy Congress, I wish to inform you that abstract submission deadline is extended to 15 February 2019.

For those who have already submitted their abstract/s, thank you. For those who are still in the process of submission, we look forward to receiving your abstract/s within the revised abstract submission period.

I am looking forward to seeing you all during the congress.

Thank you.

Sincerely,

Marivic Balagon, M.D.
Chairman
Local Scientific Organizing Committee
20th International Leprosy Congress
Philippines


LML - S Deepak, B Naafs, S Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) Interrupting transmission: the critical improvement

Leprosy Mailing List – January 30,  2019
Ref.:    (LML) Interrupting transmission: the critical improvement
From:  Joel Almeida, London and Mumbai



Dear Pieter,

We know that untreated persons with the polar LL (LLp) type of Hansen's Disease generally have the highest bacterial loads. Histopathology typically shows globi. One such patient, if left without anti-microbial protection, can nurture, harbour and excrete more viable M. leprae than hundreds of thousands of patients with the BT type of HD.

Further, genes contribute to the observed polarisation of immune response in HD (1). Monozygotic twins with disseminated types of HD were reported to show a 70% concordance of HD type while dizygotic twins showed only a 20% concordance (2). In other words, LLp status seems linked to genetic status. These patients probably start off as LLp (sometimes recognised as "de novo MB") and then remain susceptible to reinfection after MDT. 

Since M. leprae remain viable in the environment for at least 5 months in the shade (3), the spread of M. leprae despite MDT is probably maintained as follows:

From 

A. an unprotected LLp patient (before or after MDT)  

To 

B. the environment, with viability retained for 5 months

To 

C. another unprotected LLp patient, within 5 months. 

D. Repeat the cycle of transmission.

In households with several persons having the LLp genetic profile, transmission can skip the environmental step. 

This cycle of transmission probably explains why chemotherapy or chemoprophylaxis of limited duration show a disappointing impact, with children being infected and even disfigured. Re-treatment delayed until after clinical signs of relapse/reinfection still allows the spread of M. leprae, during the new sub-clinical phase.

The challenge, therefore, is two-fold:

a) Detect and identify LLp patients more promptly

b) Protect them against M. leprae for longer than the standard duration of MDT.

Such prolonged anti-microbial protection was used in Shandong Province in China. Implementation was so efficient that the outcome was steady and sustained interruption of transmission, even before the introduction of MDT (3). Interestingly, India's GDP per capita lagged behind China's by only 5 years. But India then discouraged skin smears and started withdrawing anti-microbial protection prematurely from LLp patients. Unsurprisingly, HD control in India lags China by more than 5 years. In some Indian hot spots, the observed incidence rate of HD has even been increasing. 

Recognising LLp patients more promptly is a challenge, because the clinical signs are very subtle. Sometimes, no more than a slight induration of the skin. The challenge is even greater when skin smears are unavailable.

Prolonged protection of LLp patients is easy and cheap to do. We need merely prolong MDT for an LLp patient. In ensuring this, we can realistically hope to reduce transmission. That will better protect the eyes, limbs, minds, livelihoods and relationships of not only LLp patients but also everyone else who is susceptible to M. leprae.

I spent several years examining and biopsying every single relapsed patient in a population of nearly half million people in India, followed by histopathology and mouse foot pad tests. Every single known case of HD and household contact was accounted for. That intense front-line experience tends to open one's eyes and mind to clues about what's really happening clinically, microbiologically, immunologically and epidemiologically. All of us continue to learn and ask searching questions as steadily more pieces of the HD jigsaw are uncovered by great colleagues in the basic and applied sciences.

How did our lax approach to treatment arise?

We have not routinely been stratifying outcomes of MDT by the type of HD (LLp / other). So, we condone a relapse/reinfection rate of under 'n' % per year. Unfortunately, the LLp genes are probably so infrequent that every LLp patient could show relapse/reinfection and still the relapse/reinfection rate would remain below n%. But a single LLp patient can harbour and excrete more M. leprae than hundreds of thousands of patients with the BT type of HD. Consequently, M. leprae can continue to spread with full force, even while we hug ourselves over "low" relapse/reinfection rates.

It's an easy mistake to make, and we were inexpert enough to make it. We're all human, so there's no shame in making mistakes. The important thing is to shine the light of science on our mistakes and take corrective action. 

Once we start providing prolonged anti-microbial protection (MDT) to persons with LLp, we can have reasonable hope of a sustained reduction in transmission of M.leprae just as happened in Shandong Province. Half-hearted chemical isolation does not work, as shown by the continuing transmission of M. leprae in so many MDT programmes. It has to be highly efficient and effective chemical isolation to interrupt transmission at the source. That source is mainly unprotected LLp patients, through no fault of their own.

Let's join together and make this critical improvement. We are capable of saving more limbs, eyes, minds, livelihoods and relationships among susceptible people in endemic areas. Let's do it. Let's ensure prolonged anti-microbial protection for LLp patients.

Joel Almeida


References

1. Gaschignard J, Grant AV, Thuc NV, Orlova M, Cobat A, Huong NT, et al. (2016) Pauci- and Multibacillary Leprosy: Two Distinct, Genetically Neglected Diseases. PLoS Negl Trop Dis 10(5): e0004345. https://doi.org/10.1371/journal.pntd.0004345

2. Chakravarrti MR, Vogel F. A twin study on leprosy Georg Thieme Publishers, Stuttgart, Germany; 1973.

3. Desikan KV, Sreevatsa. (1996) Extended studies on the viability of Mycobacterium leprae outside the human body. Lepr Rev 66(4):287-95 

4. Li Huan-Ying, Pan Yu-Lin, and Wang Yang. (1985) Leprosy Control in Shandong Province, China, 1955-1983; Some Epidemiological Features. Int J Lepr 53(1): 79-85.



LML - S Deepak, B Naafs, S Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com

(LML) Creating a New Face for Leprosy

Leprosy Mailing List – January 27,  2019
Ref.:   (LML)  Creating a New Face for Leprosy
From:  Diana Lockwood, London, UK


Dear Pieter,
I would be grateful if you could post this to mark World Leprosy Day.
Creating a New Face for Leprosy

This year we are launching a more positive image of leprosy in which patients are not stigmatised by their disease and regard it as a treatable infection: "The New Face of Leprosy Project".    Leprosy is characterised by pictures of severely disabled patients.  When patients do Internet searches about leprosy, they find the severe aspects of leprosy displayed, rather than information about treated people who have experienced the disease as a small part of their life. The images associated with leprosy show the extreme aspects of the disease in medical and fundraising articles.  Many leprosy patients have overcome the stigma of leprosy and developed lives and careers.

In Ethiopia, we photographed and interviewed patients in Addis Ababa, living around the main leprosy referral hospital. They had survived many setbacks and talked about these openly. Their stories were moving.  Themes that emerged from these interviews included the strength of traditional beliefs when medical problems develop; the delay in diagnosis despite patients seeing many doctors, and the challenge of leaving their rural homes to come to Addis Ababa. Several emphasized the importance of taking the anti-leprosy drugs correctly because they had problems themselves. Others needed to be on steroids for years to treat the immune-mediated reactions that complicate leprosy.  Many experienced partners leaving them and then found new partners who accepted their diagnosis.  Two men had attempted suicide. One man was deported from Kuwait.  Most wanted to give new patients hope.  Working, feeling independent financially and having a family were the things that made most of the interviewees feel strong and integrated.

This is a unique, patient-centered and positive way to document leprosy.  We are expanding this project to other countries. The project will be available on line so new patients can access to these stories.
We shall be launching this project at the Ethiopian World Leprosy Day in Gondar, Ethiopia Feb 2019.
The images and stories will be on The Lancet webpage from Jan 25 and in print from Feb 15 2019. The Link to The Lancet is
I attach the pdf of our article.
Team:
Saba Lambert, Leprosy clinician based in Ethiopia,
Alex Kumar, Doctor and photographer www.alexanderkumar.com
Eden Abate and Yilma Tesfaye interviewed the patients and translated the narratives.
Project conceived by Alexander Kumar & Diana Lockwood. All photography was self-funded by Alexander Kumar. Other elements of this work e.g. translation were funded by a social engagement grant (£1000 GBP) awarded by London School of Hygiene & Tropical Medicine (LSHTM).


LML - S Deepak, B Naafs, S Noto and P Schreuder
Contact: Dr Pieter Schreuder << editorlml@gmail.com

Editor: to our regret we did not manage to transcribe the pictures.
www.thelancet.com Published online January 25, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30158-8 1
Picturing health: a new face for leprosy
It is true that leprosy impairs and society disables. Leprosy is a neglected tropical disease and one of the most stigmatising of diseases. Images of severely disabled patients with leprosy have helped to raise awareness, attract attention, and drive donations. But these pictures are not representative of the disease. Leprosy patients deserve a better image—leprosy needs a new face. Many people with leprosy will not develop severe disease if they access treatment early. Leprosy infection is curable with 6 or 12 month courses of two or three antibiotics depending on the type of leprosy that they develop, provided free to national leprosy programmes by WHO through the Novartis Foundation.
For the New Face of Leprosy Project, we are developing a more positive image of leprosy as a treatable infection, with patients enjoying life and functioning in society. In Ethiopia, we photographed and interviewed patients in Addis Ababa who live around the main leprosy referral hospital, All Africa Leprosy Tuberculosis, Rehabilitation and Training (ALERT) Centre. The moving stories shown here are from patients talking openly, in their own words. Themes that emerged from these interviews included the strength of religious and traditional beliefs when medical problems develop, and the challenge of leaving their rural homes to come to Addis Ababa. Most of the patients we talked to initially had misconceptions, succumbed to rumours, and some even attempted suicide. Many patients had been abandoned by their families and friends. Feelings of isolation, despondency, rejection, as well as stigma and discrimination, contribute to the largely unexplored mental health burden of leprosy. The patients we spoke to emphasised the importance of taking the anti-leprosy drugs correctly, and if necessary steroids for years to treat the immune-mediated reactions. These patients persevered, they re-engaged, and they followed medical advice to not only survive but also thrive. Their shared message to new patients was that of hope. Working, being independent financially, and having a family made many of the interviewees feel accepted, integrated, and able to live on, with happy lives. As the Ethiopian proverb goes, "he who conceals his disease cannot be cured". These photographs are a unique, patient-centred, and positive way to document leprosy. We are expanding this project to other countries and more stories and images from the project will be available online in the future allowing new patients to access these stories.
*Alexander Kumar, Saba Lambert, Diana N J Lockwood
School of Population Health and Environmental Sciences, King's College London and Guy's and St Thomas' NHS Foundation Trust, London SE1 1UL, UK (AK); and London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK (SL, DNJL)
www.alexanderkumar.com
AK is a doctor and photographer. SL is a leprosy clinician based in Ethiopia. DNJL is a leprologist. The project was conceived by AK and DNJL. We thank Eden Abate (EA) and Yilma Tesfaye (YT) for assistance in interviews and translation. Interviews by AK, EA, and YT. Words by AK, DNJL, and SL. All photography was performed and self-funded by AK. Other administrative costs (translation and patient transport) were funded by the small grants scheme in public engagement from the London School of Hygiene & Tropical Medicine.
Tulu, merchant of spiritual objects, photograph by Alexander Kumar
"I am Tulu and I am 38 years old. When I first got ill, it was so difficult. I was the only one in my family and community affected by this disease. My face, ears, and arms had many small lumps. I tried various traditional medicines. Then I came to Addis; when I was told it was leprosy I felt so much anger, and so tried to kill myself twice. With medication, I saw great improvement. I and my family feel so much happier, but we went through a lot of stress. I have remarried; my second wife, Messay, had leprosy. We are both treated. I am proud of my successful business. I feel proud to take part in community life at church and at home. I earn enough to also help my family in the rural area."
Berhane, embroiderer, photograph by Alexander Kumar
Berhane was diagnosed with leprosy aged 16 years, when she developed white patches on her skin. "I am Berhane and I am 40 years old. I am married, I work and bring up my children like anyone else. For me this was an easy disease, it did not stop me from achieving all these things. My family, who brought me to Addis Ababa, and my leprosy association group, who have supported me, have been important to me. I would tell newly diagnosed patients not to be scared. Take your treatment carefully and you will be fine. You can have a family, a job, and a normal life."


Michuye, labourer, photograph by Alexander Kumar
"I am Michuye; my leprosy was diagnosed 25 years ago, when I was 14. I did not take my multidrug treatment correctly initially partly because I was following religious fasts. After explanations from the doctors, I understood the need for taking the drugs regularly. Leprosy is not like other diseases. It damages a person so slowly. If you get treatment you can change the course of the disease. At least it does not kill you! The fact that I can do any job makes me feel good. I have beautiful children. I eat, I play, I laugh. To newly diagnosed people, I would say: 'I know this feels hard just now, and that you are scared. But you will get better with treatment and things will be ok'. I think it is important to give hope and encouragement."
Argaw, farmer and student, photograph by Alexander Kumar
"I am Argaw and I am an award-winning farmer in a rural area." Argaw's leprosy was misdiagnosed many times, and his community's conviction that he was being punished by God led him to attempt suicide. He finally made his way to Addis Ababa but found the diagnosis of leprosy difficult to accept, and he interrupted his treatment. Only when he returned with a severe infection in the foot, requiring amputation and needing treatment for reactions, did he complete his course of multidrug treatment. "The thing that I would say is good now is that I have restarted my education and that, thanks to God, I did not commit suicide that night. So much has changed in my life. It has been hard, but I am in a good place."
Sewenet, cotton spinner, photograph by Alexander Kumar
"I am Sewenet and I am a cotton spinner from Gojam. I was 15 years old when I got some lumps on my body, my face, my ears. I made my way to Addis Ababa and was treated here for leprosy. When I got better, I went back to Gojam, married, and had one child. But there were many disagreements about my disease, so I left. My child grew up with my mother, but now she is here close to me. I met my second husband in Addis Ababa. I am happy that I have descendants and that I can work and help my family. I don't believe this is an inherited disease. You should see my beautiful grandchildren".
Shelemew, shoeshiner, photograph by Alexander Kumar
"I am called Shelemew. I am 18 years old. I am affected by leprosy. My mother had leprosy and died from it. A neighbour brought me and another boy to Addis for treatment. I took 1 year of treatment and my face really recovered. But soon I started getting severe pains and ended up being admitted at ALERT hospital. I had all these painful nodules and my hands were so badly affected with the numbness, the pain. I am better now. I have seen many badly affected people managing with daily life that I feel like I can work and live well. I am not less than anyone. Look, gradually I have been getting better and better. I work as a shoeshiner with another friend with leprosy, and we help each other out. I am young, and I plan to do many things. I hope for better times. My hands sometimes don't hold things well, but I still work."
Chekol, taxi driver, photograph by Alexander Kumar
Chekol is 34 years old and works as a taxi driver in Addis Ababa, his birthplace. "My leprosy was diagnosed 6 years ago, whilst I was working in Kuwait. I was put in an isolation ward and deported to Ethiopia. I was emotionally very disturbed by this experience. I would tell newly diagnosed people to be honest with your doctor, even about the difficulties at home, work, society. They can help you deal with these issues, and taking your treatment correctly will help you and give you hope. Do not worry about what others may say to you. I may have been lucky, but my journey since starting my treatment here has been very easy and smooth. Before the year is over, one sees so many changes with the treatment."
Etageg, cotton spinner, photograph by Alexander Kumar
"I am Etageg, born in Gondar. I developed leprosy when I was 10. An uncle brought me to ALERT hospital in Addis Ababa where I was treated, and I have no problems with my hands and feet. I work in a cooperative organising cotton for the spinners. Sometimes I thank the fact that I had leprosy. It was not the worst disease, especially when I compare it to my asthma. I can go live anywhere; no one can see the signs of leprosy in me. The best thing in my life is my daughter. She is at university now, studying law at Gondar. My happiness and pride when I see her are immense. I thank God."
Kebenesh, embroiderer, photograph by Alexander Kumar
"I am Kebenesh. I developed leprosy when I was 6 years old. In my family of 12 siblings, I am the only one affected. This makes me understand that it was a chance disease, a bacteria that affected me. It is not a genetic disease for sure. Because of my disabilities, I received a lot of institutional support for my education, since the age of 16. I learnt skills and now I am independent. I am married and have one girl child. The disease has left some problems in my feet, but I do not see myself as a disabled person. To people that are newly diagnosed with leprosy, I want them to see me as an example, so they can see that they can heal, can learn, work, feed themselves, and be financially independent. They need encouragement to understand that like any other disease, with some care, they can recover."
Love in the time of leprosy: Messay and Tulu, merchants of spiritual objects, photograph by Alexander Kumar
Messay and Tulu are both patients with leprosy who were successfully treated. They fell in love and are now married. "I am Messay. 39 years old. I am the wife of Tulu. We work together as merchants, he sells books and I sell holy candles. I took holy water as treatment for 7 years before I came to ALERT hospital, where the doctors explained things to me and reduced my fears about leprosy. To newly diagnosed people, I would advise them to seek treatment when the first signs of numbness or burning in hands and feet occur. I would tell them not to let any wounds grow bigger. Many people in rural areas lock themselves up or are hidden in their huts because they have smelly wounds and don't know what to do. I would tell people not to hide the ones who are unwell. People affected by leprosy can, after good treatment, work, be independent, marry, and have a family."